Related Experiment Video

Updated: Nov 9, 2025

The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

112.8K

Phosphorylated LASS2 inhibits prostate carcinogenesis via negative regulation of Wnt/β-catenin signaling

Kuangen Zhang1,2, Rui Wu1, Fang Mei1

  • 1Department of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Journal of Cellular Biochemistry
|April 14, 2021
PubMed

Insights

The tumor suppressor LASS2 degrades beta-catenin, inhibiting prostate cancer. Phosphorylation of LASS2 at serine 248 is crucial for this function, suggesting LASS2 as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • LASS2, a novel tumor suppressor, functions as a ceramide synthase.
  • Its role in prostate carcinogenesis and associated pathways remains largely uncharacterized.

Purpose of the Study:

  • To elucidate the function and pathway-related activity of LASS2 in prostate cancer.
  • To investigate the mechanism by which LASS2 regulates prostate carcinogenesis.

Main Methods:

  • Investigated LASS2's interaction with STK38, SCYL2, and ATP6V0C.
  • Utilized the ubiquitin-proteasome pathway to study beta-catenin degradation.
  • Identified serine residue 248 as a key phosphorylation site on LASS2.

Main Results:

  • LASS2 promotes beta-catenin degradation via physical interaction with STK38, SCYL2, and ATP6V0C.
  • Phosphorylation of LASS2, particularly at serine 248, is essential for beta-catenin degradation.
  • Dephosphorylation of LASS2 at serine 248 enhances prostate cancer cell growth and metastasis in vivo.

Conclusions:

  • Phosphorylated LASS2 inhibits prostate carcinogenesis by negatively regulating the Wnt/beta-catenin signaling pathway.
  • LASS2 plays a critical role in suppressing prostate cancer progression.
  • LASS2 represents a potential biomarker and therapeutic target for prostate cancer.
Keywords:
ATP6V0CLASS2SCYL2STK38Wnt/β-cateninphosphorylationprostate cancer

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K
Reconstitution Of β-catenin Degradation In Xenopus Egg Extract09:41

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

Published on: June 17, 2014

12.3K

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.5K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.0K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
14.9K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.0K